文献速递生殖医学

自动化卵母细胞回收、脱颗粒、精子制备与ICSI:概念验证研究与首批活产报告

Automated oocyte retrieval, denudation, sperm preparation, and ICSI in the IVF laboratory: a proof-of-concept study and report of the first live births.
PubMed 文献 · Hum Reprod · 2026-01-01

该概念验证研究前瞻性分配同胞卵母细胞至自动化或手动流程,使用三套自动化系统序贯完成第0天IVF操作。11例中自动化注射卵母细胞受精率64.3%(45/70),可用囊胚形成率42.2%(19/45),移植后获5例健康活产。

要点

  • 自动化序贯第0天流程在11例中实现64.3%受精与42.2%可用囊胚形成。
  • 自动化组单枚冻融囊胚移植活产率为41.7%(5/12)。
  • 仅精子制备和部分ICSI任务实现无人干预自主执行。

核心结论

  • 自动化序贯第0天IVF操作可行,并获得健康活产。
  • 自动化可能提高标准化并减少操作者变异,但需分期整合。

研究设计与样本

  • 概念验证试点研究,前瞻性分配同胞卵母细胞至自动化或手动方案。
  • 共11例(3例自体卵、8例供卵周期),在墨西哥瓜达拉哈拉Hope IVF进行,IRB批准。
  • 使用Pearl 1(精子制备)、Pearl 2(COC回收与脱颗粒)、Pearl 3(精子选择、激光制动与压电ICSI)以不同组合序贯操作。
  • 单枚冻融囊胚移植于2024年4月至10月进行。

主要发现

  • 自动化系统受精率64.3%(45/70),手动为81%(47/58)。
  • 自动化每受精卵可用囊胚形成率42.2%(19/45),手动为59.6%(28/47)。
  • 自动化组移植后获5例活产、3例生化妊娠、1例7周早期流产。
  • 自动化组单枚冻融囊胚移植活产率为5/12(41.7%)。

临床怎么用

  • 自动化可序贯完成精子制备、卵母细胞回收与脱颗粒及ICSI,支持分阶段整合。
  • 当前仍需操作者直接干预或数字控制支持,自主性限于精子制备和部分ICSI任务。

局限性

  • 样本量小,无法进行自动化与手动操作的统计学比较。
  • 部分步骤需操作者支持,自主性仅限精子制备和部分ICSI任务。
  • 研究由Conceivable Life Sciences赞助,多位作者存在公司任职、持股及专利利益冲突。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Can multiple automated systems sequentially perform Day 0 IVF procedures: (i) sperm preparation, (ii) cumulus-oocyte complex (COC) retrieval and oocyte denudation, and (iii) ICSI? SUMMARY ANSWER: Automated sequential Day 0 procedures achieved fertilization in 64.3% of injected oocytes and 42.2% usable blastocyst formation in 11 cases, resulting in five healthy live births from nine patients with positive pregnancy tests. WHAT IS KNOWN ALREADY: The Day 0 procedures-sperm preparation, oocyte handling (e.g. finding and denudation), and ICSI-rely on embryologist skill. Automation in IVF laboratories has the potential to improve reproducibility, yet its implementation remains limited. Fully automated pipetting workflows replicating embryologist activities have not yet been achieved, though partial automation of key steps such as dish preparation and ICSI has been reported. STUDY DESIGN, SIZE, DURATION: Proof-of-concept pilot study with prospective allocation of sibling oocytes to automated or manual protocols. Here, we report on Day 0 automation in 11 cases using two or three automated systems (nicknamed 'pearls') in sequence. Single vitrified/warmed blastocyst transfers occurred between April and October 2024. This work was part of a larger research programme evaluating automation across multiple IVF laboratory procedures from gamete handling through blastocyst transfer and specifically demonstrates sequential automation across multiple Day 0 procedures within a single workflow. PARTICIPANTS/MATERIALS, SETTING, METHODS: Eleven consenting patients (three autologous, eight donor egg cycles) underwent IVF/ICSI following minimal or mild stimulation. The gametes were processed using either automated or manual protocols. The automated systems-Pearl 1 (sperm preparation), Pearl 2 (COC retrieval and oocyte denudation), and Pearl 3 (sperm selection, laser immobilization, and piezo-ICSI)-were used in various combinations. Multiple AIs were developed and deployed across these systems. This IRB-approved study was conducted at Hope IVF, Guadalajara, México. MAIN RESULTS AND THE ROLE OF CHANCE: The automated systems achieved 64.3% fertilization (45/70) and 42.2% usable blastocyst formation per zygote (19/45), compared to 81% (47/58) and 59.6% (28/47) with manual procedures. Transfers from the automated arm resulted in five live births, three biochemical pregnancies, and one early loss at 7 weeks. The live birth rate per transfer of a single warmed blastocyst in the automated arm was 5/12 (41.7%). LIMITATIONS, REASONS FOR CAUTION: The small sample size prevented statistical comparison between automated and manual procedures. Some steps required operator support via direct intervention or digital control. Autonomy (defined as automated execution without human intervention) was achieved only in sperm preparation and selected ICSI tasks. A larger study using an updated system is underway. WIDER IMPLICATIONS OF THE FINDINGS: This study demonstrates the feasibility of automating Day 0 IVF procedures, with the potential to improve standardization and reduce protocol drift, fatigue, and operator variability. Our findings support a phased integration of automation to meet growing ART demands. STUDY FUNDING/COMPETING INTEREST(S): The study was sponsored by Conceivable Life Sciences. A.C.-B. is an employee, shareholder, and company officer at Conceivable Life Sciences and also holds shares in IVF 2.0. G.M.-R. is a stock option holder at Conceivable Life Sciences and has received consulting fees from both Conceivable Life Sciences and IVF 2.0. A.F.-S.F. is an employee and stock option holder at Conceivable Life Sciences. N.C.-B. is a stock option holder at Conceivable Life Sciences and has received consulting fees from the company, and he is also an employee, shareholder, and company officer at Embryotools. A.M. is a shareholder and company officer at Conceivable Life Sciences and holds shares in TMRW Life Sciences. M.A. is a stock option holder at Conceivable Life Sciences and has received consulting fees and travel support from the company; she has also received consulting fees from TMRW Life Sciences. G.S. is an employee and stock option holder at Conceivable Life Sciences and has received consulting fees from IVF 2.0. C.M. is an employee and stock option holder at Conceivable Life Sciences. E.H.-M. is an employee and stock option holder at Conceivable Life Sciences. R.V.-M. is an employee and stock option holder at Conceivable Life Sciences and has received consulting fees from IVF 2.0. V.M. is an employee and stock option holder at Conceivable Life Sciences. E.M. is an employee of Embryotools. A.V.A. has no conflicts of interest to declare. V.O.-H. is an employee and stock option holder at Conceivable Life Sciences and has received consulting fees from IVF 2.0. F.A.-G. is an employee and stock option holder at Conceivable Life Sciences. A.Á.L. is an employee and stock option holder at Conceivable Life Sciences. M.A. is an employee of Embryotools. Q.M.-A. is an employee of Embryotools. J.G.E.F. is an employee and stock option holder at Conceivable Life Sciences. L.M.C.O. has no conflicts of interest to declare. C.P.B. is an employee and stock option holder at Conceivable Life Sciences. D.J.S.-G. has no conflicts of interest to declare. J.C. is an employee, shareholder, stock option holder, and company officer at Conceivable Life Sciences and holds shares in IVF 2.0, Althea Science, TMRW Life Sciences, Kindbody, and Reproductive Healthcare. Furthermore, A.C.-B., G.M.-R., A.F.-S.F., A.M., A.Á.L., and J.C. declare inventorship on US patent 12,349,940 B2 protecting automated oocyte denudation. A.C.-B., G.M.-R., A.F.-S.F., C.M., R.V.-M., V.O.-H., E.H.-M., V.M., A.M., and J.C. declare inventorship on US patent 12,245,793 B2 protecting robotic handling systems for IVF laboratories. A.C.-B., G.M.-R., A.F.-S.F., C.M., G.S., V.M., J.C., and A.M. declare inventorship on US patent 12,178,475 B1 protecting automated sperm preparation. A.C.-B., G.M.-R., A.M., and J.C. declare inventorship on US patent 12,180,441 B1 protecting laboratory workflow automation. A.C.-B., G.M.-R., A.F.-S.F., A.M., C.M., R.V.-M., V.O.-H., N.C.-B., A.Á.L., and J.C. declare inventorship on US patent 12,268,418 B2 protecting automated oocyte preparation. A.C.-B., G.M.-R., R.V.-M., V.O.-H., N.C.-B., E.H.-M., A.M., J.C., and A.F.-S.F. declare inventorship on US patent 12,310,625 B2 protecting automated ICSI. A.C.-B., G.M.-R., A.F.-S.F., C.M., V.O.-H., and A.M. declare inventorship on US patent 12,253,516 B2 protecting optical systems for IVF automation. A.C.-B., G.M.-R., A.M., J.C., A.F.-S.F., C.M., R.V.-M., V.O.-H., G.S., N.C.-B., and J.G.E.F. declare inventorship on US patent 12,226,125 B2 protecting automated vitrification. A.C.-B., G.M.-R., C.M., R.V.-M., V.O.-H., N.C.-B., V.M., and J.C. declare inventorship on US patent US 12,478,405 B2 protecting automated dish-based sperm preparation. A.C.-B., G.M.-R., C.M., N.C.-B., M.A., A.M., and J.C. declare inventorship on a pending patent application protecting automated dish preparation technology. A.C.-B., G.M.-R., N.C.-B., and J.C. declare inventorship on a pending patent application protecting automated oocyte denudation. N.C.-B., J.C., A.M., E.H.-M., and A.C.-B. declare inventorship on a pending patent application protecting automated vitrification systems. A.C.-B., G.M.-R., V.O.-H., and J.C. declare inventorship on a pending patent application protecting COC detection technology. TRIAL REGISTRATION NUMBER: NCT06074835 (ClinicalTrials.gov, 4 October 2023).

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Chavez-Badiola A, Mendizabal-Ruiz G, Flores-Saiffe Farías A, et al. Automated oocyte retrieval, denudation, sperm preparation, and ICSI in the IVF laboratory: a proof-of-concept study and report of the first live births. Hum Reprod. 2026. PMID: 41453368. doi:10.1093/humrep/deaf240

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。